Fractyl Health, Inc. (GUTS)
| Market Cap | 146.16M +99.0% |
| Revenue (ttm) | n/a |
| Net Income | -108.00M |
| EPS | -1.05 |
| Shares Out | 158.65M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,702,827 |
| Open | 0.8389 |
| Previous Close | 0.8171 |
| Day's Range | 0.7950 - 0.9213 |
| 52-Week Range | 0.3772 - 3.0300 |
| Beta | 2.11 |
| Analysts | Strong Buy |
| Price Target | 5.24 (+468.76%) |
| Earnings Date | May 12, 2026 |
About GUTS
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. It develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. The company also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably alteri... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for GUTS stock is "Strong Buy." The 12-month stock price target is $5.24, which is an increase of 468.76% from the latest price.
News
Fractyl Health Transcript: Bank of America Global Healthcare Conference 2026
Revita aims to provide a durable, non-pharmacologic weight maintenance solution for obesity and type 2 diabetes, with pivotal clinical data and a regulatory filing expected by year-end. The company is targeting a focused commercial launch and is well-funded into 2027, while also advancing its gene therapy pipeline.
Fractyl Health Q1 Earnings Call Highlights
Fractyl Health NASDAQ: GUTS said it remains on track to report pivotal data for its Revita therapy in early fourth quarter 2026, as management highlighted clinical, regulatory and reimbursement develo...
Fractyl Health reports Q1 EPS 6c, consensus (16c)
“We believe Revita has the potential to offer a transformational new approach to durable weight maintenance and a clinically needed off ramp from GLP-1 therapy. Our first quarter results reflect…
Fractyl Health Earnings Call Transcript: Q1 2026
Q1 2026 saw improved financials and strong clinical progress, with pivotal Revita trial data expected in early Q4 and Rejuva gene therapy advancing to first-in-human studies. Cash runway extends into early 2027, with no capital raise planned before pivotal data.
Fractyl Health Earnings release: Q1 2026
Fractyl Health released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Fractyl Health Quarterly report: Q1 2026
Fractyl Health has published its Q1 2026 quarterly earnings report on May 12, 2026.
Fractyl Health Reports First Quarter 2026 Financial Results and Business Updates
Next anticipated Revita ® clinical data readouts are 1-year data from the REVEAL-1 Cohort in Q2 2026 and 1-year randomized data from the REMAIN-1 Midpoint Cohort in Q3 2026 Early Q4 2026 timing for to...
Fractyl Health Authorized to Initiate First-in-Human Trial of RJVA-001 in the Netherlands: First Gene Therapy Candidate to Enter Clinical Development for Type 2 Diabetes
Authorization advances Fractyl Health to a dual clinical-stage company, with Revita ® in pivotal development for post-GLP-1 weight maintenance and Rejuva ® entering first-in-human studies for type 2 d...
Fractyl Health to Report First Quarter 2026 Financial Results and Provide Business Updates on May 12, 2026, and Will Participate in an Upcoming Investor Conference
BURLINGTON, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company), a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat o...
Fractyl Health Proxy statement: Proxy filing
Fractyl Health filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.
Fractyl Health Proxy statement: Proxy filing
Fractyl Health filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.
Fractyl Health Earnings Call Transcript: Q4 2025
Revita's pivotal study is fully enrolled and on track for key data readouts in 2026, with strong clinical, regulatory, and commercial momentum. Financial discipline extends runway into 2027, and no capital raise is planned before pivotal data.
Fractyl Health Annual report: Q4 2025
Fractyl Health has published its Q4 2025 annual report on March 24, 2026.
Fractyl Health Earnings release: Q4 2025
Fractyl Health released its Q4 2025 earnings on March 24, 2026, summarizing the period's financial results.
Fractyl Health Annual report: Q4 2025
Fractyl Health has published its Q4 2025 annual report on March 24, 2026.
H.C. Wainwright says ‘take a breath’ after Fractyl Health selloff
AH.C. Wainwright says Fractyl Health’s (GUTS) January announcement of the six-month randomized data from the REMAIN-1 midpoint cohort evaluating Revita duodenal mucosal resurfacing maintenance after G...
Fractyl Health to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Updates on March 24, 2026
BURLINGTON, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company), a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat...
Fractyl Health completes randomization in REMAIN-1 cohort
Fractyl Health (GUTS) announced completion of participant randomization in its REMAIN-1 Pivotal Cohort, a double-blind, sham-controlled study evaluating Revita for weight maintenance following GLP-1 t...
Fractyl Health Completes Randomization in REMAIN-1 Pivotal Cohort of Revita® for Post-GLP-1 Weight Maintenance
Topline 6-month pivotal data expected in early Q4 2026 with potential FDA marketing application submission expected in late Q4 2026 Company reiterates cash runway guidance into early 2027, beyond anti...
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Fractyl Health (GUTS), 420.59% surge in interest Pipeline...
Fractyl Health, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – GUTS
LOS ANGELES--(BUSINESS WIRE)--Fractyl Health, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – GUTS.
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Fractyl Health (GUTS), 388.38% surge in interest Pipeline...
Fractyl Health price target lowered to $2 from $5 at BofA
BofA lowered the firm’s price target on Fractyl Health (GUTS) to $2 from $5 and keeps a Buy rating on the shares after the company provided new, six-month randomized controlled…
Fractyl Health downgraded to Equal Weight from Overweight at Morgan Stanley
Morgan Stanley downgraded Fractyl Health (GUTS) to Equal Weight from Overweight with a price target of $2, down from $8. In the randomized REMAIN-1 midpoint cohort at six months, Revita…
Fractyl Health Transcript: Study result
Six-month data from the REMAIN-1 pilot show Revita significantly reduces post-GLP-1 weight regain, especially in high-risk patients, with strong safety and metabolic benefits. The pivotal study is fully enrolled and on track for top-line data and potential FDA submission in late 2026.